The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both ...